NASDAQ: CORV TSX: CORV
VANCOUVER, Nov. 25, 2019 /CNW/ - Correvio Pharma Corp.
(NASDAQ: CORV) (TSX: CORV), a specialty pharmaceutical company
focused on commercializing hospital drugs, today announced that
Mark H.N. Corrigan, MD, Chief
Executive Officer of Correvio, will present at the Piper Jaffray
31st Annual Healthcare Conference. The presentation will
take place at the Lotte New York Palace on Tuesday, December 3, 2019 at 12:50p.m. ET in New
York City.
The webcast of Dr. Corrigan's Piper Jaffray presentation can be
accessed through the following link:
https://event.webcasts.com/starthere.jsp?ei=1274071&tp_key=aba0a2df74
About Correvio Pharma Corp.
Correvio Pharma Corp. is a specialty pharmaceutical company
focused on providing innovative, high-quality brands that meet the
needs of acute care physicians and patients. With a commercial
presence and distribution network covering over 60 countries
worldwide, Correvio develops, acquires and commercializes brands
for the in-hospital, acute care market segment. The Company's
portfolio of approved and marketed brands includes:
Xydalba™ (dalbavancin hydrochloride), for the treatment
of acute bacterial skin and skin structure infections (ABSSSI);
Zevtera®/Mabelio® (ceftobiprole medocaril
sodium), a cephalosporin antibiotic for the treatment of community-
and hospital-acquired pneumonia (CAP, HAP); Brinavess®
(vernakalant IV) for the rapid conversion of recent onset atrial
fibrillation to sinus rhythm; Aggrastat® (tirofiban
hydrochloride) for the reduction of thrombotic cardiovascular
events in patients with acute coronary syndrome. Correvio's
pipeline of product candidates includes Trevyent®, a
drug device combination that is designed to deliver treprostinil,
the world's leading treatment for pulmonary arterial
hypertension.
Correvio is traded on the NASDAQ Capital Market (CORV) and the
Toronto Stock Exchange (CORV). For more information, please visit
our web site www.correvio.com.
Correvio® and the Correvio Logo are the proprietary
trademarks of Correvio Pharma Corp.
Aggrastat® and Brinavess™® are trademarks
owned by Correvio and its affiliates worldwide.
Xydalba™ is a trademark of Allergan Pharmaceuticals
International Limited, and used under license.
Zevtera® and Mabelio® are trademarks owned by
Basilea Pharmaceutica International Ltd., and used under
license.
Trevyent® is a trademark of SteadyMed Ltd., a subsidiary
of United Therapeutics Corporation, and used under license.
All other trademarks are the property of their respective
owners.
View original
content:http://www.prnewswire.com/news-releases/correvio-to-present-at-the-piper-jaffray-31st-annual-healthcare-conference-300964145.html
SOURCE Correvio Pharma Corp